OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MOCP58

Molecure SA

Biotechnology & Medical ResearchVerified

Molecure SA maintains a strong liquidity position, with a current ratio of 5.79, indicating the company can easily cover its short-term liabilities with its current assets. The company holds PLN 17,077,630 in cash and equivalents, which is a significant portion of its total assets of PLN 108,785,150. The debt-to-equity ratio is low at 0.07, suggesting minimal leverage and a conservative capital structure. Profitability metrics for Molecure are currently negative, with a return on equity of -7.27% and a return on assets of -6.29%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at PLN -7,259,660, and the net income is also negative at PLN -6,839,250, reflecting ongoing operational losses. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if market conditions in its primary segment or region deteriorate. Molecure's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow is negative at PLN -2,150,990, and its free cash flow is also negative at PLN -6,336,720, indicating that it is not generating sufficient cash from operations to fund its activities or growth initiatives. The risk assessment for Molecure indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's ongoing losses and negative cash flows suggest potential future liquidity challenges if the current financial performance does not improve. Recent events, including analyst estimates, show a mixed outlook. The mean recommendation is 1.50, with one strong-buy and one buy rating, but no hold, sell, or strong-sell ratings. The mean EPS estimate is -2.90 PLN, which is significantly lower than the last actual EPS of -0.76 PLN, indicating a potential for further earnings deterioration.

30-day price · MOCP+0.05 (+0.9%)
Low$5.08High$5.99Close$5.40As of17 May, 00:00 UTC
Profile
CompanyMolecure SA
TickerMOCP.WA
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Molecure SA is a biotechnology company focused on pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of innovative therapies.

Classification. Molecure is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a high confidence level of 0.92.

Molecure SA maintains a strong liquidity position, with a current ratio of 5.79, indicating the company can easily cover its short-term liabilities with its current assets. The company holds PLN 17,077,630 in cash and equivalents, which is a significant portion of its total assets of PLN 108,785,150. The debt-to-equity ratio is low at 0.07, suggesting minimal leverage and a conservative capital structure. Profitability metrics for Molecure are currently negative, with a return on equity of -7.27% and a return on assets of -6.29%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at PLN -7,259,660, and the net income is also negative at PLN -6,839,250, reflecting ongoing operational losses. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if market conditions in its primary segment or region deteriorate. Molecure's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company's operating cash flow is negative at PLN -2,150,990, and its free cash flow is also negative at PLN -6,336,720, indicating that it is not generating sufficient cash from operations to fund its activities or growth initiatives. The risk assessment for Molecure indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the company's ongoing losses and negative cash flows suggest potential future liquidity challenges if the current financial performance does not improve. Recent events, including analyst estimates, show a mixed outlook. The mean recommendation is 1.50, with one strong-buy and one buy rating, but no hold, sell, or strong-sell ratings. The mean EPS estimate is -2.90 PLN, which is significantly lower than the last actual EPS of -0.76 PLN, indicating a potential for further earnings deterioration.
Key takeaways
  • Molecure SA has a strong liquidity position with a current ratio of 5.79 and PLN 17,077,630 in cash and equivalents.
  • The company is currently unprofitable, with a return on equity of -7.27% and a return on assets of -6.29%.
  • Molecure's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
  • Analysts have a cautiously optimistic outlook, with one strong-buy and one buy rating, but no hold, sell, or strong-sell ratings.
  • The company's operating and free cash flows are negative, indicating ongoing cash flow challenges.
  • No immediate liquidity or dilution risks were detected, but the company's financial performance may pose future challenges.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyPLN
Revenue$28.4k
Gross profit-$749.7k
Operating income-$7.3M
Net income-$6.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$2.2M
CapEx-$234.3k
Free cash flow-$6.3M
Total assets$108.8M
Total liabilities$14.7M
Total equity$94.1M
Cash & equivalents$17.1M
Long-term debt$6.6M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.2M-$13.8M-$13.6M-$14.8M
FY-3$1.6M-$16.8M-$15.3M-$17.3M
FY-2$3.7M-$32.1M-$28.4M-$25.9M
FY-1$1.4M-$32.3M-$31.5M-$28.1M
FY0$6.0M-$16.6M-$15.7M-$12.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$151.6M$141.1M
FY-3$138.0M$126.4M$53.0M
FY-2$112.3M$100.9M$53.5M
FY-1$113.4M$103.1M$15.6M
FY0$94.4M$87.4M$14.0M
PeriodOCFCapExFCFSBC
FY-4-$13.5M-$2.5M-$14.8M
FY-3-$10.0M-$3.3M-$17.3M
FY-2-$11.6M-$362.2k-$25.9M
FY-1-$57.0M-$655.3k-$28.1M
FY0-$20.3M-$12.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$28.4k-$7.3M-$6.8M-$6.3M
FQ-6$13.9k-$8.0M-$7.7M-$6.9M
FQ-5$593.8k-$6.4M-$6.3M-$5.3M
FQ-4$756.4k-$10.6M-$10.7M-$9.6M
FQ-3$597.7k-$5.5M-$5.2M-$4.4M
FQ-2$2.8M-$3.8M-$3.5M-$2.7M
FQ-1$214.8k-$5.4M-$5.3M-$4.5M
FQ0$2.4M-$1.8M-$1.7M-$667.5k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$108.8M$94.1M$17.1M
FQ-6$95.7M$86.4M$25.2M
FQ-5$87.7M$80.1M$23.2M
FQ-4$113.4M$103.1M$15.6M
FQ-3$107.4M$98.2M$35.8M
FQ-2$103.3M$94.6M$29.2M
FQ-1$97.2M$89.4M$20.1M
FQ0$94.4M$87.4M$14.0M
PeriodOCFCapExFCFSBC
FQ-7-$2.2M-$234.3k-$6.3M
FQ-6-$15.2M-$580.4k-$6.9M
FQ-5-$22.2M-$615.4k-$5.3M
FQ-4-$57.0M-$655.3k-$9.6M
FQ-3$26.1M-$4.4M
FQ-2-$9.8M-$2.7M
FQ-1-$16.6M-$4.5M
FQ0-$20.3M-$667.5k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$94.1M
Net cash$10.5M
Current ratio5.8
Debt/Equity0.1
ROA-6.3%
ROE-7.3%
Cash conversion31.0%
CapEx/Revenue-8.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricMOCPActivity
Op margin-25526.2%2.4% medp25 -91.8% · p75 12.5%bottom quartile
Net margin-24048.0%1.2% medp25 -98.4% · p75 10.4%bottom quartile
Gross margin-2636.0%45.6% medp25 29.8% · p75 66.7%bottom quartile
CapEx / revenue-824.0%-5.2% medp25 -15.8% · p75 -1.7%bottom quartile
Debt / equity7.0%9.3% medp25 0.1% · p75 43.8%below median
Observations
IR observations
Mean recommendation1.50 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-2.90 PLN
Last actual EPS-0.76 PLN
Mean revenue estimate13,100,000 PLN
Last actual revenue6,519,000 PLN
Mean EBIT estimate-70,900,000 PLN
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 07:19 UTC#3103c340
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 15:03 UTCJob: 3eb2fbce